Sunday 18 October 2026
Export RNA’s income statement to Excel — free account
Atrium Therapeutics, Inc.
RNA
Atrium Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 72.1% from fiscal 2024. Revenue growth for three consecutive years.
7.67
0.15
−1.92%
Follow RNA
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 |
+1 more quarter Free account |
P/S ratio |
8.20 | 0.00 | — | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
(58.60) | (7.34) | — | (21.19) | |
P/B ratio |
1.07 | 0.98 | — | 0.00 | |
Price to Tangible BV |
1.07 | 0.98 | — | 0.00 | |
EV/Sales |
(1.22) | 0.00 | — | 0.00 | |
EV/EBITDA |
0.57 | 0.00 | — | 0.00 | |
EV/Operating CF |
0.59 | 0.00 | — | 0.00 | |
EV/FCF |
0.59 | 0.00 | — | 0.00 | |
Quick Ratio |
8.39 | 12.91 | 0.00 | — | |
Current Ratio |
8.73 | 13.04 | 0.07 | — | |
Net Debt/EBITDA |
11.73 | 15.64 | — | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.20 | — | — | — | |
Operating CF/Net income |
0.19 | 1.87 | — | 0.92 | |
Capex/Depreciation |
(0.39) | (13.89) | — | (3.37) | |
Research and Development Expense of Revenue |
510.75% | 84.83% | — | 345.54% | |
Selling, General and Administrative Expense of Revenue |
342.18% | 103.17% | — | 88.85% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
29.73% | 62.20% | — | 44.19% | |
Graham Net Nets |
0.91 | 0.99 | — | (0.27) | |
Graham Number |
0.00 | 0.00 | — | 0.00 | |
Earnings Yield |
(24.82%) | (24.82%) | — | (24.82%) | |
Free Cash Flow Yield |
(25.24%) | 0.00% | — | 0.00% | |
Revenue per Share |
0.18 | 1.15 | — | 0.22 | |
Operating CF per Share |
(0.23) | (1.82) | — | (0.70) | |
Capex per Share |
0.00 | (0.12) | — | (0.02) | |
Free Cash Flow per Share |
(0.23) | (1.94) | — | (0.71) | |
Cash per Share |
15.45 | 15.66 | — | 0.00 | |
Shareholders Equity per Share |
12.54 | 13.69 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
12.54 | 13.69 | 0.00 | 0.00 | |
Free Cash Flow |
(3.96) | (33.24) | — | (12.17) | |
Working Capital |
243.54 | 263.66 | (38.96) | — | |
Capital Expenditures |
(0.04) | (2.10) | — | (0.27) | |
Net Current Asset Value |
209.12 | 227.31 | (68.22) | 0.00 | |
EV/EBIT |
0.57 | 0.00 | — | 0.00 | |
Capex to Sales |
0.01 | 0.11 | — | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Assets |
140.26 | — | — | — |
Columns are period end dates